Submitted:
07 July 2025
Posted:
08 July 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design and Setting
2.2. Participants and Recruitment
2.3. Data Collection Procedures
2.4. Outcome Measures
2.5. Demographic and Clinical Variables
2.6. Statistical Analysis
3. Results
3.1. Participant Characteristics
3.2. WeeFIM Domain Scores
3.3. Self-Care Domain
3.4. Mobility Domain
3.5. Cognitive Domain
3.6. Age-Related Patterns
3.7. Functional Independence Categories
3.8. Factors Associated with Functional Outcomes
3.9. Specific Challenging Activities
4. Discussion
4.1. Cognitive Function Preservation
4.2. Mobility Challenges and Adaptive Strategies
4.3. Self-Care Independence and Development
4.4. Impact of Early Intervention Services
4.5. Environmental Factors and Accessibility
4.6. Lifespan Functional Development
4.7. Clinical Implications and Future Directions
4.8. Study Limitations
5. Conclusion
Author Contributions
Ethics Approval
Consent for Publication
Data Access
Recognition
Competing Interests
Financial Support
References
- Waller, D.K.; Correa, A.; Vo, T.M.; Wang, Y.; Hobbs, C.; Langlois, P.H.; Pearson, K.; Romitti, P.A.; Shaw, G.M.; Hecht, J.T. The population-based prevalence of achondroplasia and thanatophoric dysplasia in selected regions of the US. Am. J. Med. Genet. A 2008, 146A, 2385-2389. [CrossRef]
- Oberklaid, F.; Danks, D.M.; Jensen, F.; Stace, L.; Rosshandler, S. Achondroplasia and hypochondroplasia. Comments on frequency, mutation rate, and radiological features in skull and spine. J. Med. Genet. 1979, 16, 140-146. [CrossRef]
- Shiang, R.; Thompson, L.M.; Zhu, Y.-Z.; Church, D.M.; Fielder, T.J.; Bocian, M.; Winokur, S.T.; Wasmuth, J.J. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 1994, 78, 335-342. [CrossRef]
- Rousseau, F.; Bonaventure, J.; Legeai-Mallet, L.; Pelet, A.; Rozet, J.-M.; Maroteaux, P.; Merrer, M.L.; Munnich, A. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 1994, 371, 252-254. [CrossRef]
- Horton, W.A.; Hall, J.G.; Hecht, J.T. Achondroplasia. Lancet 2007, 370, 162-172. [CrossRef]
- Pauli, R.M. Achondroplasia: a comprehensive clinical review. Orphanet J. Rare Dis. 2019, 14, 1. [CrossRef]
- Hoover-Fong, J.E.; Schulze, K.J.; McGready, J.; Barnes, H.; Scott, C.I. Age-appropriate body mass index in children with achondroplasia: interpretation in relation to indexes of height. Am. J. Clin. Nutr. 2008, 88, 364-371. [CrossRef]
- Richette, P.; Bardin, T.; Stheneur, C. Achondroplasia: from genotype to phenotype. Joint Bone Spine 2008, 75, 125-130. [CrossRef]
- Ireland, P.J.; Donaghey, S.; Mcgill, J.; Zankl, A.; Ware, R.S.; Pacey, V.; Ault, J.; Savarirayan, R.; Sillence, D.; Thompson, E.; Townshend, S.; Johnston, L.M. Development in children with achondroplasia: a prospective clinical cohort study. Dev. Med. Child Neurol. 2012, 54, 532-537. [CrossRef]
- Hunter, A.G.W.; Hecht, J.T.; Scott, C.I. Standard weight for height curves in achondroplasia. Am. J. Med. Genet. 1996, 62, 255-261. [CrossRef]
- Ottenbacher, K.J.; Msall, M.E.; Lyon, N.; Duffy, L.C.; Ziviani, J.; Granger, C.V.; Braun, S.; Feidler, R.C. The WeeFIM instrument: its utility in detecting change in children with developmental disabilities. Arch. Phys. Med. Rehab. 2000, 81, 1317-1326. [CrossRef]
- Msall, M.E.; DiGaudio, K.M.; Duffy, L.C. Use of functional assessment in children with developmental disabilities. Phys. Med. Reh. Clin. N. 1993, 4, 517-527. [CrossRef]
- Msall, M.E.; DiGaudio, K.; Rogers, B.T.; LaForest, S.; Catanzaro, N.L.; Campbell, J.; Wilczenski, F.; Duffy, L.C. The Functional Independence Measure for Children (WeeFIM). Conceptual basis and pilot use in children with developmental disabilities. Clin. Pediatrics 1994, 33, 421-430. [CrossRef]
- Uniform Data System for Medical Rehabilitation. Guide for the Functional Independence Measure for Children (WeeFIM) of the Uniform Data System for Medical Rehabilitation, Version 5.1; Foundation Activities: Buffalo, NY, 1997.
- Kopits, S.E. Orthopedic complications of dwarfism. Clin. Orthop. Relat. Res. 1976, 114, 153-179. [CrossRef]
- King, J.A.; Vachhrajani, S.; Drake, J.M.; Rutka, J.T. Neurosurgical implications of achondroplasia. J. Neurosurg. Pediatr. 2009, 4, 297–306. [CrossRef]
- Savarirayan, R.; Irving, M.; Bacino, C.A.; Bostwick, B.; Charrow, J.; Cormier-Daire, V.; Le Quan Sang, K.H.; Dickson, P.; Harmatz, P.; Phillips, J.; Owen, N. C-type natriuretic peptide analogue therapy in children with achondroplasia. N. Engl. J. Med. 2019, 381, 25-35. [CrossRef]
- Legeai-Mallet, L.; Savarirayan, R. Novel therapeutic approaches for the treatment of achondroplasia. Bone 2020, 141, 115579. [CrossRef]
- World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013, 310, 2191-2194. [CrossRef]
- Committee on Bioethics. Informed consent in decision-making in pediatric practice. Pediatrics 2016, 138, e20161485. [CrossRef]
- Trotter, T.L.; Hall, J.G; Committee on Genetics. Health supervision for children with achondroplasia. Pediatrics 2005, 116, 771-783. [CrossRef]
- Ireland, P.; Pacey, V.; Zankl, A.; Edwards, P.; Johnson, L.; Savarirayan, R. Optimal management of complications associated with achondroplasia. Appl. Clin. Genet. 2014, 7, 117-125. [CrossRef]
- Schulz, K.F.; Altman, D.G.; Moher, D.; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010, 340, c332. [CrossRef]
- Cohen, J. Statistical Power Analysis for the Behavioral Sciences; 2th ed.; Lawrence Erlbaum Associates: Hillsdale, NJ, 1988. [CrossRef]
- Faul, F.; Erdfelder, E.; Lang, A.-G.; Buchner, A. G*power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 2007, 39, 175-191. [CrossRef]
- Ottenbacher, K.J.; Taylor, E.T.; Msall, M.E.; Braun, S.; Lane, S.J.; Granger, C.V.; Lyons, N.; Duffy, L.C. The stability and equivalence reliability of the functional independence measure for children (WeeFIM)®. Dev. Med. Child. Neurol. 1996, 38, 907-916. [CrossRef]
- Braun, S.L.; Granger, C.V. A practical approach to functional assessment in pediatrics. Occup. Ther. Pract. 1991, 2, 46-51.
- Msall, M.E.; Digaudio, K.M.; Duffy, L.C, LaForest S, Braun S, Granger CV. WeeFIM: normative sample of an instrument for tracking functional independence in children. Clin. Pediatr. (Phila) 1994, 33, 431-438. [CrossRef]
- Koo, T.K.; Li, M.Y. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J. Chiropr. Med. 2016, 15, 155-163. [CrossRef]
- Granger, C.V.; Hamilton, B.B.; Keith, R.A.; Zielezny, M.; Sherwin, F.S. Advances in functional assessment for medical rehabilitation. Top. Geriatr. Rehabil. 1986, 1, 59-74. [CrossRef]
- Sperle, P.A.; Ottenbacher, K.J.; Braun, S.L.; Lane, S.J.; Nochajski, S. Equivalence reliability of the functional independence measure for children (WeeFIM®) administration methods. Am. J. Occup. Ther. 1997, 51, 35-41. [CrossRef]
- McCabe, M.A.; Granger, C.V. Content validity of a pediatric functional independence measure. Appl. Nurs. Res. 1990, 3, 120-122. [CrossRef]
- Msall, M.E.; Buck, G.M.; Rogers, B.T.; Merke, D.; Catanzaro, N.L.; Zorn, W.A. Risk factors for major neurodevelopmental impairments and need for special education resources in extremely premature infants. J. Pediatr. 1991, 119, 606-614. [CrossRef]
- Kidd, D.; Stewart, G.; Baldry, J.; Johnson, J.; Rossiter, D.; Petruckevitch, A.; Thompson, A.J. The functional independence measure: a comparative validity and reliability study. Disabil. Rehabil. 1995, 17, 10-14. [CrossRef]
- Dodds, T.A.; Martin, D.P.; Stolov, W.C.; Deyo, R.A. A validation of the functional independence measurement and its performance among rehabilitation inpatients. Arch. Phys. Med. Rehab. 1993, 74, 531-536. [CrossRef]
- Ziviani, J.; Ottenbacher, K.; Shephard, K.; Foreman, S.; Astbury, W.; Ireland, P. Concurrent validity of the Functional Independence Measure for Children (WeeFIM™) and the Pediatric Evaluation of Disabilities Inventory in children with developmental disabilities and acquired brain injuries. Phys. Occup. Ther. Pediatr. 2001, 21, 91-101. [CrossRef]
- von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J. Clin. Epidemiol. 2008, 61, 344–349. [CrossRef]
- Vandenbroucke, J.P.; von Elm, E.; Altman, D.G.; Gøtzsche, P.C.; Mulrow, C.D.; Pocock, S.J.; Poole, C.; Schlesselman, J.J.; Egger, M.; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. Epidemiology 2007, 18, 805–835. [CrossRef]
- IBM Corp. IBM SPSS Statistics for Windows, Version 28.0; IBM Corp: Armonk, NY, 2021.
- R Core Team. R: A language and environment for statistical computing; R Foundation for Statistical Computing: Vienna, Austria, 2023.
- Shapiro, S.S.; Wilk, M.B. An analysis of variance test for normality (complete samples). Biometrika 1965, 52, 591-611. [CrossRef]
- Field, A. Discovering Statistics Using IBM SPSS Statistics; 5th ed.; Sage Publications: London, 2018.
- Tabachnick, B.G.; Fidell, L.S. Using Multivariate Statistics; 7th ed.; Pearson: Boston, 2019.
- Hair, J.F.; Black, W.C.; Babin, B.J.; Anderson, R.E. Multivariate Data Analysis; 8th ed.; Cengage Learning: Boston, 2019; Vol. 8.
- Bonferroni CE. Teoria statistica delle classi e calcolo delle probabilità. Pubblicazioni del R Istituto Superiore di Scienze Economiche e Commerciali di Firenze 1936, 8, 3-62.



| Characteristic | n (%) or Mean ± SD |
| Age at assessment (years) | 18.3 ± 10.2 |
| Range | 6-47 |
| Age groups | |
| Early childhood (6-8 years) | 8 (15.7) |
| School age (9-12 years) | 18 (35.3) |
| Adolescence (13-18 years) | 20 (39.2) |
| Young adults (19+ years) | 5 (9.8) |
| Gender | |
| Male | 29 (56.9) |
| Female | 22 (43.1) |
| Age at diagnosis | |
| Infancy (<1 year) | 40 (78.4) |
| Early childhood (1-3 years) | 8 (15.7) |
| School age (4-11 years) | 2 (3.9) |
| Adolescence (12-18 years) | 1 (2.0) |
| Genetic testing performed | 35 (68.6) |
| FGFR3 mutation confirmed | 35 (100.0) |
| Early intervention services | 42 (82.4) |
| Physical therapy | 38 (74.5) |
| Occupational therapy | 35 (68.6) |
| Speech therapy | 28 (54.9) |
| Age Group | n | Self-Care | Mobility | Cognition | Total WeeFIM |
| Early childhood (3-6 years) | 8 | 43.8 ± 7.2 | 26.4 ± 4.8 | 32.1 ± 2.9 | 98.3 ± 15.2 |
| School age (7-12 years) | 18 | 51.2 ± 5.8 | 31.8 ± 3.2 | 33.8 ± 1.8 | 114.8 ± 12.6 |
| Adolescence (13-18 years) | 20 | 54.1 ± 4.2 | 33.2 ± 2.1 | 34.9 ± 1.2 | 121.4 ± 8.3 |
| Young adults (19+ years) | 5 | 55.6 ± 0.9 | 34.4 ± 0.8 | 35.0 ± 0.0 | 124.8 ± 2.1 |
| Overall | 51 | 52.8 ± 6.4 | 32.1 ± 4.2 | 34.2 ± 2.1 | 115.1 ± 14.8 |
| F-statistic (p-value) | 12.34 (<0.001) | 15.67 (<0.001) | 8.92 (<0.001) | 18.47 (<0.001) |
| Independence Level | Self-Care n (%) | Mobility n (%) | Cognition n (%) |
| Complete independence (6-7) | 42 (82.4) | 38 (74.5) | 48 (94.1) |
| Modified dependence (4-5) | 9 (17.6) | 13 (25.5) | 3 (5.9) |
| Complete dependence (1-3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Variable | β Coefficient | Standard Error | t-value | p-value | 95% CI |
| Age at assessment | 0.68 | 0.12 | 5.67 | <0.001 | 0.44-0.92 |
| Early intervention | 0.42 | 0.15 | 2.80 | 0.008 | 0.12-0.72 |
| Gender (male) | 0.18 | 0.19 | 0.95 | 0.347 | -0.20-0.56 |
| Age at diagnosis | -0.15 | 0.14 | -1.07 | 0.289 | -0.43-0.13 |
| Genetic testing | 0.08 | 0.16 | 0.50 | 0.620 | -0.24-0.40 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).